Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

rozanolixizumab 5zilucoplan 4eculizumab 4efgartigimod alfa 3Rituximab 2Prednisone 2Amifampridine 2thymoglobulin 1satralizumab 1rhoA GTP-Binding Protein 1ravulizumab 1iscalimab 1inebilizumab 1gamma-Globulins 1Thymectomy 1Sugars 1Steroids 1Sodium Chloride 1Robotic Surgical Procedures 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mesna 1Hizentra 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Fluid Therapy 1Cyclophosphamide 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myasthenia Gravis × satralizumab × Clear all
NCT04963270 2025-02-28

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Hoffmann-La Roche

Phase 3 Terminated
188 enrolled 40 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡